Aadi bioscience grants new ceo dave lennon, ph.d. inducement award under nasdaq listing rule 5635 (c)(4)

Los angeles , oct. 3, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced that an equity award has been granted to its new president and chief executive officer, dave lennon, ph.d., on october 2, 2023, the first date of his employment (the "grant date"), in accordance with the aadi bioscience, inc. 2023 inducement plan (the "plan").
AADI Ratings Summary
AADI Quant Ranking